Reviva Pharmaceuticals - RVPH Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $14.33
  • Forecasted Upside: 861.97%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$1.49
▼ -0.02 (-1.32%)

This chart shows the closing price for RVPH by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Reviva Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RVPH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RVPH

Analyst Price Target is $14.33
▲ +861.97% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Reviva Pharmaceuticals in the last 3 months. The average price target is $14.33, with a high forecast of $17.00 and a low forecast of $12.00. The average price target represents a 861.97% upside from the last price of $1.49.

This chart shows the closing price for RVPH for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 4 polled investment analysts is to buy stock in Reviva Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/21/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/21/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/19/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/17/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/16/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/15/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/14/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/13/2024

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/11/2024HC WainwrightLower TargetBuy ➝ Buy$20.00 ➝ $14.00Low
5/28/2024BenchmarkReiterated RatingSpeculative Buy ➝ Speculative Buy$17.00 ➝ $17.00Low
4/22/2024HC WainwrightReiterated RatingBuy ➝ Buy$20.00Low
4/16/2024BenchmarkReiterated RatingSpeculative Buy ➝ Speculative Buy$17.00Low
3/25/2024HC WainwrightReiterated RatingBuy ➝ Buy$20.00Low
2/20/2024HC WainwrightReiterated RatingBuy ➝ Buy$20.00Low
12/26/2023HC WainwrightReiterated RatingBuy ➝ Buy$20.00Low
10/31/2023HC WainwrightBoost TargetBuy ➝ Buy$10.00 ➝ $20.00Low
10/30/2023Roth MkmReiterated RatingBuy ➝ Buy$12.00Low
9/20/2023Roth CapitalReiterated RatingBuyLow
9/20/2023Roth MkmInitiated CoverageBuy$12.00Low
8/16/2023HC WainwrightReiterated RatingBuy ➝ Buy$10.00Low
6/8/2023BenchmarkInitiated CoverageBuy$17.00Low
5/3/2023Maxim GroupBoost Target$10.00 ➝ $18.00Low
4/4/2023HC WainwrightReiterated RatingBuy$20.00Low
1/25/2023HC WainwrightReiterated RatingBuy$10.00Low
11/1/2022Maxim GroupBoost TargetBuy$3.00 ➝ $10.00Low
11/1/2022Alliance Global PartnersInitiated CoverageBuy$16.00Low
1/24/2022HC WainwrightInitiated CoverageBuy$10.00High
7/26/2021Maxim GroupInitiated CoverageBuy$10.00High
(Data available from 6/13/2019 forward)

News Sentiment Rating

0.05 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/16/2023
  • 0 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
12/16/2023
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/15/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
2/14/2024
  • 0 very positive mentions
  • 11 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
3/15/2024
  • 2 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
4/14/2024
  • 2 very positive mentions
  • 17 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
5/14/2024
  • 1 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
6/13/2024

Current Sentiment

  • 1 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Reviva Pharmaceuticals logo
Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. Reviva Pharmaceuticals Holdings, Inc. was founded in 2018 and is headquartered in Cupertino, California.
Read More

Today's Range

Now: $1.49
Low: $1.49
High: $1.53

50 Day Range

MA: $2.43
Low: $1.31
High: $3.79

52 Week Range

Now: $1.49
Low: $1.21
High: $6.80

Volume

21,757 shs

Average Volume

315,974 shs

Market Capitalization

$41.60 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Reviva Pharmaceuticals?

The following sell-side analysts have issued reports on Reviva Pharmaceuticals in the last year: Benchmark Co., HC Wainwright, Roth Capital, and Roth Mkm.
View the latest analyst ratings for RVPH.

What is the current price target for Reviva Pharmaceuticals?

3 Wall Street analysts have set twelve-month price targets for Reviva Pharmaceuticals in the last year. Their average twelve-month price target is $14.33, suggesting a possible upside of 862.0%. Benchmark Co. has the highest price target set, predicting RVPH will reach $17.00 in the next twelve months. Roth Mkm has the lowest price target set, forecasting a price of $12.00 for Reviva Pharmaceuticals in the next year.
View the latest price targets for RVPH.

What is the current consensus analyst rating for Reviva Pharmaceuticals?

Reviva Pharmaceuticals currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe RVPH will outperform the market and that investors should add to their positions of Reviva Pharmaceuticals.
View the latest ratings for RVPH.

What other companies compete with Reviva Pharmaceuticals?

How do I contact Reviva Pharmaceuticals' investor relations team?

Reviva Pharmaceuticals' physical mailing address is 19925 STEVENS CREEK BLVD. SUITE 100, CUPERTINO CA, 95014. The company's listed phone number is (408) 501-8881 and its investor relations email address is ir.revivapharma.com. The official website for Reviva Pharmaceuticals is www.revivapharma.com. Learn More about contacing Reviva Pharmaceuticals investor relations.